GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (MEX:TAK N) » Definitions » Cyclically Adjusted Revenue per Share

Takeda Pharmaceutical Co (MEX:TAK N) Cyclically Adjusted Revenue per Share : MXN167.47 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Takeda Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2025 was MXN44.453. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN167.47 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Takeda Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Takeda Pharmaceutical Co was 4.70% per year. The lowest was 1.10% per year. And the median was 2.05% per year.

As of today (2025-06-28), Takeda Pharmaceutical Co's current stock price is MXN287.95. Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN167.47. Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.72.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takeda Pharmaceutical Co was 3.13. The lowest was 1.34. And the median was 1.79.


Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 211.13 200.67 162.30 140.55 167.47

Takeda Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 140.55 137.95 176.39 176.02 167.47

Competitive Comparison of Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


;
;

Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Takeda Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=44.453/111.1000*111.1000
=44.453

Current CPI (Mar. 2025) = 111.1000.

Takeda Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 35.825 98.400 40.449
201509 40.732 98.500 45.942
201512 43.769 98.100 49.569
201603 40.283 97.900 45.714
201606 48.512 98.100 54.941
201609 50.514 98.000 57.266
201612 52.671 98.400 59.469
201703 44.031 98.100 49.866
201706 46.516 98.500 52.466
201709 45.157 98.800 50.779
201712 53.975 99.400 60.328
201803 43.534 99.200 48.756
201806 51.057 99.200 57.182
201809 45.628 99.900 50.743
201812 55.422 99.700 61.759
201903 40.255 99.700 44.858
201906 48.343 99.800 53.817
201909 47.656 100.100 52.893
201912 47.680 100.500 52.709
202003 53.417 100.300 59.169
202006 54.927 99.900 61.085
202009 52.464 99.900 58.346
202012 50.886 99.300 56.933
202103 46.000 99.900 51.157
202106 55.224 99.500 61.662
202109 49.888 100.100 55.370
202112 51.566 100.100 57.233
202203 46.528 101.100 51.130
202206 46.977 101.800 51.269
202209 44.991 103.100 48.482
202212 50.451 104.100 53.843
202303 40.703 104.400 43.315
202306 41.018 105.200 43.318
202309 39.256 106.200 41.067
202312 40.563 106.800 42.196
202403 36.714 107.200 38.050
202406 44.111 108.200 45.293
202409 50.321 108.900 51.338
202412 48.176 110.700 48.350
202503 44.453 111.100 44.453

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Takeda Pharmaceutical Co  (MEX:TAK N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=287.95/167.47
=1.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takeda Pharmaceutical Co was 3.13. The lowest was 1.34. And the median was 1.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co Headlines

No Headlines